{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T20:19:43Z","timestamp":1780345183882,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1 EY011751"],"award-info":[{"award-number":["UG1 EY011751"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jaapos.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T11:13:05Z","timestamp":1620299585000},"page":"177-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity"],"prefix":"10.1016","volume":"25","author":[{"given":"Gloria J.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra S.","family":"Stinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon F.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Grace","family":"Prakalapakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2021.02.002_bib1","doi-asserted-by":"crossref","first-page":"e20183061","DOI":"10.1542\/peds.2018-3061","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2021.02.002_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaapos.2021.02.002_bib3","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2021.02.002_bib4","first-page":"212","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000-1006","volume":"131","author":"Hu","year":"2013","journal-title":"Published correction in Arch Ophthalmol"},{"key":"10.1016\/j.jaapos.2021.02.002_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jaapos.2021.02.002_bib6","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","article-title":"Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study","volume":"135","author":"Wallace","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2021.02.002_bib7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ophtha.2018.05.001","article-title":"A\u00a0dosing study of bevacizumab for retinopathy of prematurity: late recurrences and additional treatments","volume":"125","author":"Wallace","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2021.02.002_bib8","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jamaophthalmol.2020.0334","article-title":"Short-term outcomes after very low-dose intravitreous bevacizumab for retinopathy of prematurity","volume":"138","author":"Wallace","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jaapos.2021.02.002_bib9","first-page":"128","article-title":"Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study","volume":"22","author":"Morrison","year":"2018","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2021.02.002_bib10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/pan.14008","article-title":"Anesthesia management of laser photocoagulation for retinopathy of prematurity: a retrospective review of perioperative adverse events","volume":"30","author":"Kaur","year":"2020","journal-title":"Paediatr Anaesth"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853121000975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853121000975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T20:24:59Z","timestamp":1761078299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853121000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1091853121000975"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2021.02.002","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic laser versus continued surveillance after initial bevacizumab treatment for retinopathy of prematurity","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}